Melanoma Clinical Trial
A Phase I/II Study of GMX1777 in Combination With Temozolomide for the Treatment of Metastatic Melanoma
Summary
Obatoclax Mesylate (GMX1777) is a water-soluble, intravenously-administered pro-drug of GMX1778. GMX1777 is rapidly converted to GMX1778 in vivo. GMX1778 has potent anti-tumor activity against a variety of cell lines and models from different tumor origins.
Full Description
GMX1777 will be administered as 3-Hour Infusions in Combination with Temozolomide taken orally for the treatment of Metastatic Melanoma. GMX1777 infusion will be given on either day 1, days 1 and 3, or days 1,3, and 5 every 4 weeks. Temozolomide will be administered on 5 consecutive days every 4 weeks. No investigational or commercial agents or therapies other than those described may be administered with the intent to treat the patient's malignancy.
Eligibility Criteria
Inclusion Criteria:
Histologically or cytologically confirmed metastatic melanoma
Up to 1 prior chemotherapy regimen allowed; prior immunotherapy allowed
Normal organ and marrow function
Willing to submit to blood sampling for planned PK/PD analyses
Ability of understand and willingness to sign a written informed consent
Exclusion Criteria:
No other investigational or commercial agents or therapies
Prior exposure to GMX1777, GMX1778 or CHS828
Patients with uncontrolled, intercurrent illness
Pregnant or breastfeeding women
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Philadelphia Pennsylvania, 19104, United States
How clear is this clinincal trial information?
Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.